Work

Japan Approves Datopotamab Deruxtecan for the Treatment of Adult Patients with HR positive, HER2 negative Unresectable/Recurrent Breast Cancer after Prior Chemotherapy

Year: 2024

Type: article

Abstract: Datopotamab deruxtecan (Datroway®; Daiichi Sankyo, previously known as DS-1062 and TROP2 ADC, see ADC Drug Map) an antibody-drug conjugate or ADC, being jointly developed and commercialized globally by Daiichi Sankyo and AstraZeneca, has been approved in Japan for the treatment of adult patients with hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) unresectable or recurrent breast cancer after prior chemotherapy.

Source: ADC Review / Journal of Antibody-drug Conjugates

DOI: 10.14229/jadc.2024.12.27.001

Authors: Peter Hofland, Danielle Garcia

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W4405905748

FWCI:

Cites: 7

Cited by:

Related to: 10